Laboratory Development and Shared Antigenicity of Two Prototype Candidate Citrobacter Freundii Vaccines
Keywords:
Antibody, Antisera, Shared antigenicit, Agglutinin, Absorption.Abstract
Cirobacter freundii are currently standing as a newly emerged human pathogen causing several infection types .It may take an outbreak pattern of nosocomial infectious disease. Thus, a prototype candidate Citrobacter freundii human uro-pathogen were aimed to be laboratory developed in two versions .The first was heat killed intact[CFKV] and the second was stealth live cell wall defective[CFSLV] vaccines. Both versions were found to be; safe ,immunogenic and effective on lapin immune and challenge models. The immune efficacy was up to 80% for CF SLV and 60% for the CFKV vaccines. CFKV and CFSLV vaccines were with no mortality but with mild short lasting morbidity. The criteria of the laboratory developed C. fruendii vaccines were matching that of typhoid vaccine Ty21a.The stealth FCSLV of freundii vaccine has shown shared antigenicity with CFKV vaccine version. Such shared antigenicity was found to be of bilateral nature both in quantitative and qualitative terms. CFKV and CFSLV vaccines induced humoral antibody responses which may be of Th2 dependent B cell responses. T cell responses are far from being operable in the immune efficacy of these vaccines, since C .fruendii are neither obligate nor facultative intracellular parasites . Vaccine lapin cross challenge models are waiting to be explored in a future work.
References
. J.G.Whalen,T.W. Mully , J.C. English . “Spontaneous Citrobacter fruendii infection in an immunocompramized patients . ” Arch.dermatol, 143(1), 124-125,2007.
. L-H.Liu.,N-Y.Wang ,A.Y.Wu ,C.C.Lin, C-M.Lee, C-P.Liu, “Citrobacter fruendii bacterium:Risk factors of mortality and prevalence of resistance genes. ” J.Microbiol.Immunol.Inf . , 51 , 565-572.
. N.Kamada , K.Sakamoto , J.L.Puente , G.Nunez , “ Humoral immunity in gut selectivity target phenotypically virulent attaching and facing bacteria for intraluminal elimination. ” Cell.Host.and Microbe. ,17,617-627 ,2015.
. M.T.Anderson , L.A.Mitchell , L.Zhao , L.T.Mobley, “Citrobacter fruendii fitness during blood stream infection ” .Sci.Rep. ,8,11792,2018.
. M.F.Darwish, “Exo-polysaccharide vaccine from Citrobacter fruendii induce immunity against inflectional pathogen ” .Kuf.Uni.J.Biol. , 2 ,150-160 , 2017.
. A.A.ALThahab. “Immunological effects of Citrobater fruendii ell free culture in rabbits. ” Baby.Uni.J. ,2(23),605-609 ,2015.
. C.P.Simmons , S.Clart , Ghaem-Maghami. Et al., “Control role for B lymphocyte and CD4+ T cells in immunity to infection with attaching effacing pathogen C.rodentium. ” Inf.Imm.71(9) ,5077-5086 ,2003.
. Q.N.Thewaini. “Biology of Cell wall Defective Microbes From Persistent Pyuria And Haematuria. ” Ph.D. , Thesis , Babylon University, IRAQ, 2002.
. J.J.Sharp, L. Dienes , “Carbohydrate containing antigens from L.forms Proteus. ” J. Bateriol. 78,343-351 ,1959.
. M.A.N.ALShahery,I.M.S.Shnawa, “The immunological adjuvanicity of sunflower oil. ” Vet.Med.Giza. ,37(2) ,291-298 , 1989.
. NIH., understanding Vaccines. , Publication Number ,98-4219, 24-25 , 1998.
. S.A.Plotkin ,Phrma Fact Book. ,109 Pages,52-64 , 2012.
. C.D. Stevens ,Clinical Immunology And Serology:A Laboratory Perspective,3rd.ed . , Philadelphia :F.A.Davis Company ,108-116,137-142.2010.
. R.Sakazaki,T.J.Donovan,” Serology,epidemiology of Vibrio cholera, V. mimicus. ” , Methods In Microbiology, ASM ,1984.16:271-289.
. I.M.S.Shnawa, “A Study on the serogrouping of Vibrio cholera[NAG]. ” Zag.Vet.J.IV(A),161-169,1982.
. A.Collioud ,S.A. Rothen , G. Dietrich, “Developing and manufacturing of attenuated live bacterial vaccines . ” , Bio.Pharm.Int. , 6 ,Suppl ,1-12 , 2008.
. K.P.Rangan, N. Rangan , “Citrobacter :An emerging care associated urinary tract pathogen” .Urol.Ann.5(4):313-314.,2013.
. S.D.Gobal , S.Raj, “ incidence of Citrobacter urinary tract infection in type II diabetes and its relationship to glycemia control . ” Int.Cont.Med.Res. , 4(1) ,60-62.
. L.Bery ,M.Brigl , M.B.Brenner, “ CD4+ T cell effector function and co-stimulatory requirements essential for surviving mucosal infection with attaching effacing pathogen. ” Inf.Immun.74(1) ,673-681 , 2006.
. I.M.S.Shnawa,Q.N.O.Thewaini, “Lapin evaluation parameters for the prototype experimental stealth bacterin prepared from human uropathogen . ” Int.J.Sci. :Basic.Appl.Res.35(1):12-18.,2017.
. B.Adler, Leptospira and Leptospirosis. , Springer,280,2014.
. A.Rabson, I.Roitt ,P.J. Delves . Really Essential Medical Immunology 2nd ed. USA, Blackwellpublications,2005,50-61.
. M.W.Steward . Antibodies:Their Structure And Function.N.Y.Chapman And Hall .1984,55-60.
. S.H.E.Kaufmann et al.,TBVA2020. Advancing Tuberculosis Vaccines from discovery to clinical development.Front. Immunol.8:1203.
Downloads
Published
How to Cite
Issue
Section
License
Authors who submit papers with this journal agree to the following terms.
